

Letter to the Editor

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

S Novello^{*,1}, GV Scagliotti¹, R Rosell², MA Socinski³, J Brahmer⁴, J Atkins⁵, C Pallares⁶, R Burgess⁷, L Tye⁸, P Selaru⁸, E Wang⁸, R Chao⁸ and R Govindan⁹

¹University of Turin, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole, 10, Orbassano, Turin 10043, Italy; ²Catalan Institute of Oncology, Barcelona, Spain; ³University of North Carolina, Chapel Hill, NC, USA; ⁴Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Cockeysville, MD, USA; ⁵Southeastern Medical Oncology Center, Goldsboro, NC, USA; ⁶Hospital de San Pablo, Oncology, Barcelona, Spain; ⁷Eastern Carolina Internal Medicine, Pollockville, NC, USA; ⁸Pfizer Global Research and Development, La Jolla, CA, USA; ⁹Washington University School of Medicine, St Louis, MO, USA

British Journal of Cancer (2010) 102, 1311. doi:10.1038/sj.bjc.6605629 www.bjcancer.com
Published online 30 March 2010
© 2010 Cancer Research UK

Sir,

We acknowledge the discussion points raised by Schöffski *et al* (2010), both in their letter and in their prospective evaluation of sunitinib-induced hypothyroidism published in this journal in 2008 (Wolter *et al*, 2008).

We reported on a small, open-label, phase II clinical trial of sunitinib on a continuous daily dosing schedule in patients with advanced NSCLC and, as noted in the discussion section of the paper, the primary end point of this trial (the reporting of at least five objective responses) was not reached. However, despite the low overall response rate, we were encouraged by the time-to-event results obtained, which we feel are concordant with a signal of activity and with time-to-event data observed on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off; Socinski *et al*, 2008). Furthermore, as this was not a phase III trial designed to definitively assess the activity of sunitinib in patients with lung cancer, we feel justified in reporting intriguing observations pertaining to antitumour activity. Conclusive efficacy statements cannot, and have not, been made in this paper and we believe that the interpretation of the trial data was suitably guarded.

Schöffski *et al* also suggest correlations between the effect of sunitinib on thyroid function and the incidence of fatigue in our trial. There were few data to support such a correlation at the time our trial was designed; consequently, thyroid function measurement was not part of the clinical protocol. Nevertheless, we acknowledge that 53–85% of oncology patients treated with sunitinib develop thyroid test abnormalities, and a substantial percentage develop clinical manifestations of thyroid dysfunction (Desai *et al*, 2006; Rini *et al*, 2007). Guidance for the use of sunitinib in its licensed indications is available and recommends baseline laboratory measurement of thyroid function, with hyper- and hypothyroidism treated as per standard medical practice. Studies investigating the impact of sunitinib therapy on thyroid function are ongoing.

ACKNOWLEDGEMENTS

Editorial/medical writing support was provided by Nicola Crofts PhD at ACUMED (Tytherington, UK) and was funded by Pfizer Inc.

REFERENCES

Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. *Ann Intern Med* 145: 660–664

Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. *J Natl Can Inst* 99: 81–83

Schöffski P, Garfield DH, Herbergs A, Wolter P (2010) Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors. *Br J Cancer* 102: 1309–1310

Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. *J Clin Oncol* 26: 650–656

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. *Br J Cancer* 99: 448–454

*Correspondence: Dr S Novello; E-mail: silvia.novello@unito.it
Published online 30 March 2010